Navigation Links
Braeburn and Camurus Announce Initiation of a Phase 2 Study in Opioid Dependent Patients with Moderate to Severe Chronic Pain

PRINCETON, N.J. and LUND, Sweden, Feb. 22, 2016 /PRNewswire/ --Braeburn Pharmaceuticals and Camurus announced today that the first patients have been dosed with CAM2038, weekly and monthly subcutaneous buprenorphine injections, in a pharmacokinetic study of opioid dependent patients with chronic pain.

The primary objective of this Phase 2 study is to assess the steady state pharmacokinetics of buprenorphine after repeated doses in opioid dependent patients with chronic pain, including effects of injection into different subcutaneous sites. This study will also explore the effect of CAM2038 on chronic pain, along with evaluation of safety and tolerability.

"This marks the fourth clinical study that has been started in the last five months for CAM2038, including two Phase 3 trials in opioid dependence. The ability to use CAM2038 in multiple injection sites would allow physicians the flexibility to personalize treatments," said Behshad Sheldon, President and CEO, Braeburn Pharmaceuticals. "Our goal is to provide a suite of best-in-class long-acting treatment options tailored to the individual needs of patients suffering from opioid dependence and chronic pain."

"Patients that suffer from chronic pain and are also opioid dependent are a difficult population to treat," said the principal investigator Dr. Greg Sullivan, medical director at Parkway Medical Center in Birmingham, Alabama. "By using a long acting buprenorphine injectable, these patients would no longer be required to take medication multiple times per day. Buprenorphine also guards against hyperanalgesia and opiate tolerance, both of which are problems with conventional opiates."

"CAM2038 has the potential to offer effective and safe around-the-clock pain relief, without risks of abuse and diversion. The pharmacological properties of buprenorphine together with long-acting release from the FluidCrystal formulation could also decrease risks of respiratory depression and overdose mortality associated with current opioid pain treatments," said Fredrik Tiberg, President and CEO, Camurus.

About Braeburn Pharmaceuticals
Braeburn Pharmaceuticals, an Apple Tree Partners company, is a pill-free pharmaceutical company delivering precision medicine in neuroscience. In September 2015 the Food and Drug Administration (FDA) accepted for review Braeburn's New Drug Application for its lead candidate, Probuphine, a six-month buprenorphine implant for treatment of opioid dependence. The Agency has set May 27, 2016 as the target date for action.

Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in these conditions, which are often complicated by stigma and present significant public health challenges. Braeburn's investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Candidates include: Probuphine®, a six-month buprenorphine implant for treatment of opioid addiction; CAM2038, weekly and monthly subcutaneous injection depot formulations of buprenorphine for treatment of opioid addiction and pain; a risperidone six-month implant for treatment of schizophrenia; and a novel molecule, ATI-9242, for treatment of schizophrenia. More information on Braeburn, can be found at

About CAM2038
The investigational CAM2038 buprenorphine subcutaneous injection products for treatment of opioid addiction and pain are being developed as once-weekly and once-monthly formulations, each with multiple doses, to cover all phases of treatment from initiation through maintenance. The CAM2038 products are designed for administration by healthcare personnel to ensure proper delivery that minimizes the risks of diversion, abuse, misuse, and accidental exposure. The CAM2038 products have been evaluated in three Phase 1/2 clinical trials, which evaluated the safety and tolerability as well as pharmacokinetic and pharmacodynamics properties of the products in a total of 176 individuals (opioid-dependent patients and healthy volunteers under naltrexone blockage). The CAM2038 products are also being developed for treatment of chronic pain, combining the effective analgesic properties of buprenorphine with the long acting release provided by the FluidCrystal® injection depot.

About Camurus
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus' clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company's share is listed on Nasdaq Stockholm under the ticker "CAMX". For more information, visit

Media contacts:
Fredrik Tiberg, President & CEO
Tel: +46 (0)46 286 46 92

Sherry Feldberg


Logo -
Logo -

SOURCE Braeburn Pharmaceuticals, Inc.; Camurus
Copyright©2016 PR Newswire.
All rights reserved

Related medicine technology :

1. Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments
2. Dr. Frank Young of Braeburn Pharmaceuticals Receives 2015 Distinguished Scientist Award from American College of Toxicology
3. Braeburn Pharmaceuticals And Titan Pharmaceuticals Announce Date Of FDA Advisory Committee Review Of Probuphine For Opioid Addiction
4. Braeburn Pharmaceuticals and Camurus announces start of Phase 3 trial of long-acting buprenorphine treatments for opioid dependence
5. Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce FDA Advisory Committee Recommends Approval of Probuphine, First 6-Month Implant to Treat Opioid Addiction
6. Camurus samarbetspartner köper licensrättighet till långtidsverkande peptidläkemedel
7. Rhythm and Camurus Announce License Agreement for Extended Release FluidCrystal Setmelanotide
8. Pharmagen Announces First Quarter 2013 Results
9. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year
10. Vasomedical Announces Financial Results for the First Quarter of 2013
11. TSI Announces 2013 Respiratory Protection Roadshow Training Dates and Locations
Post Your Comments:
(Date:8/3/2020)... ... ... What is the purpose of sleep? Most of us would answer, “to rest” — but ... we feel sick or tired from a long day at work, or working all day ... sleeping habits or our own daily choices of how we spend our time. Why is ...
(Date:7/31/2020)... , ... July 31, 2020 , ... ... partnership with Netquest, a global panel and data collection provider, recently released the ... adults, across the United Kingdom, Germany and France. , “COVID-19 continues to have ...
(Date:7/22/2020)... ... 22, 2020 , ... With the new school year rapidly ... A new 8 page white paper, “Infectious Disease Control for Schools Using Germ-Fogger™”, ... Germ-Fogger™ disinfecting-fogger is uniquely well suited to the requirements of disinfecting primary school, ...
Breaking Medicine Technology:
(Date:8/7/2020)... ... August 07, 2020 , ... Mary J's Cannabis , ... assistance of dicentra Cannabis Consulting . , The store, which operates out ... is the first of many locations as the company plans to expand across Canada. ...
(Date:8/5/2020)... ... August 05, 2020 , ... Atlanta Magazine partnered with ... complete the “Top Doctor” survey. The mission of Castle Connolly Medical Ltd. is ... physicians and key medical leaders were asked to identify outstanding doctors in their ...
(Date:8/5/2020)... ... August 05, 2020 , ... In its often-heroic ... unprecedented challenges. Regardless of the obstacle - shortages of tests, ventilators and ICU ... the cancellation or postponement of all nonessential services - providers across the country ...
(Date:8/5/2020)... Fla. (PRWEB) , ... August 05, 2020 , ... ... today announced the appointments of Kathleen Cruger as Director of Clinical Services and ... accelerate the company’s growth. , “ChronWell has achieved incredible growth as ...
(Date:8/5/2020)... ... 05, 2020 , ... CentrAlert, Inc. today announced the launch of ... COVID-19 information. Know NOW!, which is available for Apple and Android ... one easy-to-use mobile application. , “When COVID-19 first hit, there was so much that ...
Breaking Medicine News(10 mins):